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valuation at Follow-Up of Cell TherapyTable 1 Eva uation at Fo ow-Up of Cell Therapy
T
Baseli
Clinical data
Age, yrs 45
Sex, male 33
NYHA functional class for dyspnea
I 0
II 0
III 29 (7
IV 12 (2
Mortality
KCCQ
Functional status score 51.19
Clinical summary score 59.81
Echocardiography data
End-systolic volume, ml 137.3
End-diastolic volume, ml 176.7
Ejection fraction, % 22.5
Treatment at 3 yrs
ACE inhibitor or ARB (ramipril equivalent), % taking drug
Dose, mg
Beta-blocker (carvedilol equivalent), % taking drug
Dose, mg
alues are mean  SD or n (%) of patients. Continuous variables were compared using a Wilcoxo
ifferences in mortality were compared by the Fisher exact test. All analyses were performed with
years for treatment group. †p  0.05 between treatment arm and control arm.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; KCCQ  Kansas Clease note: The AIIMS Stem Cell Study Group: Sandeep Seth, MD, DM, Balram
hargava, MD, DM, Rajiv Narang, MD, DM, Ruma Ray, MD, MRC Path, Sujata
103 pmol/l [868 pg/ml]), had a greater clinical benefit from
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cohanty, PHD, Gurpreet Gulati, MD, Sanjeev Sharma, Lalit Kumar, MD, DM,
apil Kumawat, Neeraj Parakh, Praloy Chakroborty, Balram Airan, Panangipalli
enugopal, MS, MCh. This work was done with the Research Funds of the All India
nstitute of Medical Sciences under the Stem Cell Research Program at the Centre of
xcellence for Stem Cell Research, Department of Biotechnology, Government of
ndia.
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ent Arm (n 41) Control Arm (n  40)
3 Yrs Baseline 3 Yrs
49 9
35
4 (9) 0 9
22 (54) 14 (35) 10 (25)
6 (15) 12 (30) 18 (45)
9 (22) 14 (35) 12 (30)
12 (24.4) 14 (30)
67.02 21.8* 51.52 18.12 52.74 18.8†
75.22 18.31* 59.95 18.44 61.17 19†
120 52* 145.7 74.7 147.8 79.9†
166.5 65.5 184.9 94.6 187.7 98.8
28.4 11.8* 20.8 9.3 21.2 9.2†
41 (100) 40 (100)
7.5 1.2 7.4 1.7
29 (70) 29 (72)
12.5 5 12.1 3
ple test (for within-group differences) and the Mann-Whitney U test (between-group differences).
or Windows (version 10.0.1, 1999, SPSS Inc., Chicago, Illinois). *p  0.05 between baseline and
iomyopathy Questionnaire; NYHA  New York Heart Association.mononuclear cell delivery to dilated cardiomyopathy patients: a clinical
trial. Afr J Biotechnol 2008; 7:207–10.Letters to the Editortatins and Heart Failure
leland et al. (1) report that patients with less severe heart failure
HF) due to ischemic heart disease (IHD), as indicated by lower
evels of N-terminal pro–B-type natriuretic peptide (lower tertile,osuvastatin (hazard ratio [HR]: 0.65; 95% confidence interval
CI]: 0.47 to 0.88, p  0.005), despite the lower absolute event
ate, contrary to the results of the original study (2).
We reported that treatment with atorvastatin (mean dose 23
g/day) of 800 IHD patients resulted in a reduction of 50% (HR:
.50; 95% CI: 0.27 to 0.94, p  0.021) in new cases or worseningreatm
ne
15
1)
9)
19.90
20.27
62.6
76.40
8.3
n 2-sam
SPSS fases of HF requiring hospitalization versus 800 IHD patients
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April 13, 2010:1643–7eceiving usual care (3). Moreover, atorvastatin treatment reduced
composite of total and coronary mortality, coronary morbidity,
nd stroke by 45% (HR: 0.55; 95% CI: 32 to 84, p  0.006) in
atients with preexisting HF (ejection fraction 30%) at baseline
3). In similar patients, the Treating to New Targets study (n 
0,001) results showed that compared with the 10-mg/day dose of
torvastatin, an 80-mg/day dose of atorvastatin in patients with
table IHD significantly reduced hospitalizations for HF (HR:
.74; 95% CI: 0.59 to 0.94; p 0.0116) (4). In a post hoc analysis,
his benefit was only observed in patients with a history of HF
HR: 0.59; 95% CI: 0.4 to 0.88; p  0.009) (4).
Taken together, the data in the preceding text suggest that in
ilder HF, coronary events can be modified by statins and this
ay be the most important driver of outcome. In contrast, in
evere cases of HF, progressive loss of pump function is not
ubstantially improved by statin treatment, especially when admin-
stered in addition to optimal treatment of HF.
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osuvastatin and
ardiovascular Continuum
hen Time Is Important
e read with interest the article by Cleland et al. (1) about
hether N-terminal pro-B-type natriuretic peptide (NT-proBNP)
o
gould be used to identify the degree of severity of heart failure at
hich statins become ineffective in the CORONA (Controlled
osuvastatin Multinational Trial in Heart Failure) trial. Although
any trials have demonstrated that statins reduce cardiovascular
orbidity and mortality in many patients with ischemic heart
isease, this does not seem to occur in those with ischemic heart
ailure, as the CORONA trial showed (2). As a result, there must
e a cutoff point at which treatment with a statin becomes futile.
n this study, the investigators demonstrated that patients in the
owest tertile of NT-proBNP had the best prognosis and, if
ssigned to rosuvastatin rather than placebo, had a greater reduc-
ion in the primary end point (hazard ratio: 0.65; 95% confidence
nterval: 0.47 to 0.88) than patients in the other tertiles (p 
.0192). As a consequence, patients with heart failure due to
schemic heart disease who had NT-proBNP values 103 pmol/l
868 pg/ml) may benefit from rosuvastatin (1).
However, this seems to occur not only in the ischemic heart
isease, but in the overall cardiovascular continuum, and the
ifferent results obtained with rosuvastatin in the different scenar-
os of several randomized clinical trials clearly exemplify it (3).
ardiovascular disease is a continuum, from risk factors to organ
amage and finally to overt clinical cardiovascular disease and
nd-stage renal disease. Although it is very relevant to control all
ardiovascular risk factors along the continuum, the beneficial
ffects of therapy are not the same, depending on the stage at
hich the treatment is started. Thus, if statins are prescribed at
arlier stages, the improvement in cardiovascular prognosis will be
arkedly higher than in later stages (3). For example, in the
UPITER trial (Justification for the Use of Statins in Primary
revention: An Intervention Trial Evaluating Rosuvastatin) (4),
hich included patients without cardiovascular disease but with
levated high-sensitivity C-reactive protein levels, the benefits of
reatment with rosuvastatin were outstanding. However, at very
dvanced stages such as heart failure (CORONA) (2) or at
nd-stage renal disease (AURORA [A Study to Evaluate the Use
f Rosuvastatin in Subjects on Regular Hemodialysis: An Assess-
ent of Survival and Cardiovascular Events]) (5), the benefits were
ery modest or even null. However, even at advanced stages, as
leland et al. (1) reported, not all the patients are the same. Because
ortality is very high, all the approaches aimed at differentiating
hich patients will benefit more from available therapies are crucial.
n this case, NT-proBNP values could likely be used as a good
redictor of the clinical results with a statin therapy.
All these data emphasize that to really improve a cardiovascular
rognosis, it is critical to start the treatment with statins as soon as
ossible in the cardiovascular continuum. If the therapy starts when a
atient is already at end-stage disease, it is most likely too late.
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